Journal
LEUKEMIA
Volume 25, Issue 2, Pages 201-210Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2010.215
Keywords
chronic myeloid leukemia; adverse events; intolerance; dasatinib; imatinib
Categories
Funding
- Bristol-Myers Squibb
- Novartis
Ask authors/readers for more resources
BCR-ABL-targeting tyrosine kinase inhibitors (TKIs) constitute the cornerstone of treatment for chronic myeloid leukemia. Although these agents are normally safe and effective, they can cause side effects that lead to intolerance and necessitate switching to an alternative treatment. In this review, we describe side effects that occur during treatment with imatinib, nilotinib or dasatinib-the currently approved TKI treatments for chronic myeloid leukemia-including class effects and key differences in safety profiles. We also describe how common side effects can be effectively managed and offer a working definition of intolerance that may be useful to clinicians when they consider switching between TKIs. Leukemia (2011) 25, 201-210; doi:10.1038/leu.2010.215; published online 23 September 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available